We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Cardiometabolic diseases, including type 2 diabetes (T2DM) and cardiovascular disease (CVD), are common. Approximately one in three deaths annually are caused by CVD in Aotearoa New Zealand (AoNZ)(1). The Mediterranean dietary pattern is associated with a reduced risk of cardiometabolic disease in epidemiological and interventional studies(2,3). However, implementing the Mediterranean diet into non-Mediterranean populations can be challenging(4). Some of these challeanges include facilitating consumption of unfamiliar foods and the cultural and social context of food consumption. AoNZ produces a rich source of high-quality foods consistent with a Mediterranean dietary pattern. He Rourou Whai Painga is collaborative project combining contributions from food industry partners into a Mediterranean Diet pattern and providing foods, recipes and other support to whole household/whānau. The aim was to test if a New Zealand food-based Mediterranean diet (NZMedDiet) with behavioural intervention improves cardiometabolic health and wellbeing in individuals at risk. This presentation will review the background to the research, the process of forming a collaboration between researchers and the food industry, the design and implementation of a complex study design (see protocol paper)(5), with results from the initial randomised controlled trial. We conducted several pilot studies(6,7,8) to inform the final design of the research, which was a combination of two randomised controlled trials (RCT 1 and 2) and a longitudinal cohort study. RCT-1 compared 12-weeks of the NZMedDiet to usual diet in participants with increased cardiometabolic risk (metabolic syndrome severity score (MetSSS) >0.35). The intervention group were provided with food and recipes to meet 75% of their energy requirements, supported by a behavioural intervention to improve adherence. The primary outcome measure was MetSSS after 12 weeks. Two hundred individuals with mean (SD) age 49.9 (10.9)yrs with 62% women were enrolled with their household/whānau. After 12 weeks, the mean (SD) MetSSS was 1.0 (0.7) in the control (n = 98) and 0.8 (0.5) in the intervention (n = 102) group; estimated difference (95% CI) of -0.05 (-0.16 to 0.06), p=0.35. A Mediterranean diet score (PyrMDS) was greater in the intervention group 1.6 (1.1 to 2.1), p<0.001, consistent with a change to a more Mediterranean dietary pattern. Weight reduced in the NZMedDiet group compared with control (-1.9 kg (-2.0 to -0.34)), p=0.006 and wellbeing, assessed by the SF-36 quality of life questionnaire, improved across all domains p<0.001. In participants with increased cardiometabolic risk, food provision with a Mediterranean dietary pattern and a behavioural intervention did not improve a metabolic risk score but was associated with reduced weight and improved quality of life.
Unanchored population-adjusted indirect comparisons (PAICs) such as matching-adjusted indirect comparison (MAIC) and simulated treatment comparison (STC) attracted a significant attention in the health technology assessment field in recent years. These methods allow for indirect comparisons by balancing different patient characteristics in single-arm studies in the case where individual patient-level data are only available for one study. However, the validity of findings from unanchored MAIC/STC analyses is frequently questioned by decision makers, due to the assumption that all potential prognostic factors and effect modifiers are accounted for. Addressing this critical concern, we introduce a sensitivity analysis algorithm for unanchored PAICs by extending quantitative bias analysis techniques traditionally used in epidemiology. Our proposed sensitivity analysis involves simulating important covariates that were not reported by the comparator study when conducting unanchored STC and enables the formal evaluating of the impact of unmeasured confounding in a quantitative manner without additional assumptions. We demonstrate the practical application of this method through a real-world case study of metastatic colorectal cancer, highlighting its utility in enhancing the robustness and credibility of unanchored PAIC results. Our findings emphasise the necessity of formal quantitative sensitivity analysis in interpreting unanchored PAIC results, as it quantifies the robustness of conclusions regarding potential unmeasured confounders and supports more robust, reliable, and informative decision-making in healthcare.
Māori, the Indigenous population of Aotearoa New Zealand, face a substantial burden of nutrition-related diseases, especially obesity and type 2 diabetes. Weight loss, through dietary change, is a central component of obesity and diabetes prevention and management; however, most approaches have not been designed with or evaluated specifically for Māori. The aim of this study was to review literature on the enablers and barriers to dietary change, for Māori.
Design:
Relevant literature published from January 2000 to May 2024 was identified by searches in Medline (Ovid), Embase (Ovid), Scopus, Indigenous health (informit), CINAHL (EBSCO), Web of Science and NZResearch. Studies included Māori and reflected enablers and barriers to dietary change for individuals/whānau (families). Data identifying the aims, methods, interventions, location, population studied and identified enablers and barriers to dietary change and responsiveness to Māori were extracted. Enablers and barriers to dietary change were mapped to a New Zealand Indigenous health framework, the Meihana model.
Setting:
Settings included studies based in Aotearoa New Zealand, where participants were free living and able to determine their dietary intake.
Participants:
Studies included at least 30 % Māori participants.
Results:
Twenty-two of the seventy-seven identified records met the inclusion criteria. Records included a diverse range of research approaches.
Conclusions:
Using a relevant Indigenous model, this study highlights that multiple and diverse enablers and barriers to dietary change exist for Māori and the critical importance of developing interventions, in close partnership with Indigenous communities, grounded in Indigenous understandings of health.
Cardiometabolic diseases are highly prevalent in Aotearoa New Zealand(1). Dietary intake is a modifiable risk factor for such diseases and certain dietary patterns, specifically the Mediterranean diet (MedDiet), are associated with improved metabolic health(2). This study aims to test whether an intervention of a Mediterranean dietary pattern incorporating high quality New Zealand foods (NZMedDiet pattern) using behaviour change science can improve the metabolic health of participants and their household/whānau. This is a multi-centre, three-stage trial, with two randomised controlled trials (RCTs), both parallel groups, superiority trials, and a longitudinal cohort study. The first RCT (RCT1) is a comparison of the NZMedDiet pattern implemented using behaviour science compared to usual diet for 12 weeks, and the second (RCT2) is a behaviour-change intervention compared to no intervention for 12 weeks, administered after participants have been exposed to the intervention in RCT1. The third stage is a longitudinal cohort study where all participants are followed for up to a year. The primary outcome measure for each stage is the metabolic syndrome severity score (MetSSS). Two hundred index participants and their household/whānau have been recruited and randomised into the trial. Participants are from four centres, two of which are University research units (University of Auckland (n = 57) and University of Otago, Christchurch (n = 60)), one a community-based traditional meeting place (Tu¯ Kotahi Māori Asthma and Research Trust at Ko¯kiri Marae in Lower Hutt, Wellington (n = 19)), and the other based at a hospital-based research unit (the Centre for Endocrine Diabetes and Obesity Research (CEDOR) in Wellington (n = 64). The trial will test whether the NZMedDiet pattern and behaviour change support improves the cardiometabolic health of people in New Zealand.
Mica domains have received less attention in the literature than smectite quasi-crystals. This study was conducted to determine whether mica crystals form domains in suspension, the conditions in which those domains exist, and the distribution of adsorbed Na and Ca ions in the domains. Particle size distributions and electrophoretic mobilities (EM) of Silver Hill illite in suspension densities of 0.5 g liter−1 were determined by photon correlation spectroscopy (PCS). Solutions at salt concentration from 2 to 10 mmolc liter−1, sodium adsorption ratio (SAR) from 0 to ∞ (mmol liter−1)0.5, and pH values 5, 7, and 9 were used to prepare the clay suspensions. The particle size of Silver Hill illite suspensions showed a bimodal distribution. Through PCS measurements at low angles, the second peak of the bimodal distribution of the illite was found to be associated with the rotational movement of the b-dimension of the particles. Illite domains broke down in the range of SAR 10 to 15 (mmol liter−1)0.5 equivalent to exchangeable sodium percentages (ESP) of 13 to 18. Illite thus demonstrates a similar stability to smectites that require ESP ≈ 15 to disaggregate quasi-crystals. The EM of the illite particles increased drastically when the SAR increased from 2 to 10 (mmol liter−1)0.5. This increase in EM could not be explained exclusively by the change in the particle size. Cation demixing is required to explain the increase of the zeta potential at the shear plane. The EM of the Silver Hill illite was doubled when the pH increased from 5 to 9 at SAR > 15, but no pH effect was found when SAR < 15. The effect of pH on the EM at SAR values > 15 can be understood if we consider that at SAR > 15 most of the particles are single platelets. The relative importance of variable charge on single platelets or crystals is apparently greater than on domains because the pH affected the mobility of the individual crystals but not the mobility of the domains. The combination of particle size distribution and EM data gives additional information about the zero point of charge of the variable charge, also called point of zero net proton charge (PZNPC) of the clay. For Silver Hill illite, we estimate a PZNPC value between 5 and 7.
The objective of this research was to evaluate managed access policy in England, drawing upon the expertise of a range of stakeholders involved in its implementation.
Methods
Seven focus groups were conducted with payer and health technology assessment representatives, clinicians, and representatives from industry and patient/carer organizations within England. Transcripts were analyzed using framework analysis to identify stakeholders’ views on the successes and challenges of managed access policy.
Results
Stakeholders discussed the many aims of managed access within the National Health Service in England, and how competing aims had affected decision making. While stakeholders highlighted a number of priorities within eligibility criteria for managed access agreements (MAAs), stakeholders agreed that strict eligibility criteria would be challenging to implement due to the highly variable nature of innovative technologies and their indications. Participants highlighted challenges faced with implementing MAAs, including evidence generation, supporting patients during and after the end of MAAs, and agreeing and reinforcing contractual agreements with industry.
Conclusions
Managed access is one strategy that can be used by payers to resolve uncertainty for innovative technologies that present challenges for reimbursement and can also deliver earlier access to promising technologies for patients. However, participants cautioned that managed access is not a “silver bullet,” and there is a need for greater clarity about the aims of managed access and how these should be prioritized in decision making. Discussions between key stakeholders involved in managed access identified challenges with implementing MAAs and these experiences should be used to inform future managed access policy.
To identify dietary self-monitoring implementation strategies in behavioural weight loss interventions.
Design:
We conducted a systematic review of eight databases and examined fifty-nine weight loss intervention studies targeting adults with overweight/obesity that used dietary self-monitoring.
Setting:
NA.
Participants:
NA.
Results:
We identified self-monitoring implementation characteristics, effectiveness of interventions in supporting weight loss and examined weight loss outcomes among higher and lower intensity dietary self-monitoring protocols. Included studies utilised diverse self-monitoring formats (paper, website, mobile app, phone) and intensity levels (recording all intake or only certain aspects of diet). We found the majority of studies using high- and low-intensity self-monitoring strategies demonstrated statistically significant weight loss in intervention groups compared with control groups.
Conclusions:
Based on our findings, lower and higher intensity dietary self-monitoring may support weight loss, but variability in adherence measures and limited analysis of weight loss relative to self-monitoring usage limits our understanding of how these methods compare with each other.
Cognitive dysfunction is an important aspect of depression that includes problems with thinking, concentration and memory. Research suggests that the cognitive aspect of depression is highly prevalent and has a significant impact on patient functioning. Currently, cognitive dysfunction in depression is largely unrecognised, unmonitored and untreated.
Aims
We aim to define cognitive dysfunction in clinical depression (major depressive disorder) and explore its detection and management in the UK, highlighting priority areas to be addressed.
Methods
A modified Delphi method was used as the process to gain consensus. A multi-stakeholder steering committee of depression experts (including psychiatrists, psychologists, primary care physicians, and representatives from occupational therapy and a depression charity) provided the key themes and, through round-table discussion, developed draft statements. The main areas of focus were burden, detection and management of cognitive dysfunction in depression. These statements formed a questionnaire to be reviewed by 150–200 health-care professionals with an involvement in the management of depression, with level of agreement noted as ‘strongly disagree’, ‘disagree’, ‘don’t know/uncertain’, ‘agree’ or ‘strongly agree’. Responses to the questionnaire will be analysed (very high agreement [> 66%] or very low agreement [< 33%]) and the steering committee will revise and finalise the consensus statements, and identify priority areas for future consideration. The steering committee was initiated and supported by the pharmaceutical company Lundbeck Ltd, through an educational grant. Lundbeck Ltd did not influence content.
Results
Results of the questionnaire and the evolution of the final consensus statements will be presented.
Disclosure of interest
The authors have not supplied their declaration of competing interest.
Sociocultural and social cognitive theories have begun to make a lasting imprint on English Language Teaching (ELT) and learning as it is undertaken and understood today across a range of contexts (Steffensen and Kramsch ). This chapter reports on a study conducted with English language learners involved in Literature Circles (LCs) over an extended period and centres on an analysis of the discourse generated within these post-reading, group discussions. The chapter begins by contextualising LCs as a vehicle for reader response and collaborative engagement within an ecological perspective to second language (L2) development. Drawing on sociocultural theory (Lantolf, Thorne and Poehner ) and its application to collaborative engagement in a language learning environment, the discourse presented undergoes an ecologically grounded, dialogical analysis. This analysis interprets examples from the group conversations as affordances for language development identified as an emergent phenomenon, co-constructed and mediated by the support of peers, the shared reading experience and relevant scaffolding. The current study suggests that this dynamic combines collaborative interaction and interpersonal communication with ecosocial processes to promote spoken L2 development, where deep processing of shared interpretation, critical evaluation, collective noticing and expression of affect are externalised within the discussions.
Apolipoprotein E (APOE) E4 is the main genetic risk factor for Alzheimer’s disease (AD). Due to the consistent association, there is interest as to whether E4 influences the risk of other neurodegenerative diseases. Further, there is a constant search for other genetic biomarkers contributing to these phenotypes, such as microtubule-associated protein tau (MAPT) haplotypes. Here, participants from the Ontario Neurodegenerative Disease Research Initiative were genotyped to investigate whether the APOE E4 allele or MAPT H1 haplotype are associated with five neurodegenerative diseases: (1) AD and mild cognitive impairment (MCI), (2) amyotrophic lateral sclerosis, (3) frontotemporal dementia (FTD), (4) Parkinson’s disease, and (5) vascular cognitive impairment.
Methods:
Genotypes were defined for their respective APOE allele and MAPT haplotype calls for each participant, and logistic regression analyses were performed to identify the associations with the presentations of neurodegenerative diseases.
Results:
Our work confirmed the association of the E4 allele with a dose-dependent increased presentation of AD, and an association between the E4 allele alone and MCI; however, the other four diseases were not associated with E4. Further, the APOE E2 allele was associated with decreased presentation of both AD and MCI. No associations were identified between MAPT haplotype and the neurodegenerative disease cohorts; but following subtyping of the FTD cohort, the H1 haplotype was significantly associated with progressive supranuclear palsy.
Conclusion:
This is the first study to concurrently analyze the association of APOE isoforms and MAPT haplotypes with five neurodegenerative diseases using consistent enrollment criteria and broad phenotypic analysis.